Danny Sugimoto
5PUBLICATIONS
4CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Apr 01, 2024
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.Elena A Christofides, Orlando Puente, Paul Norwood
|Jan 24, 2023
Efficacy and safety of semaglutide for weight management: evidence from the STEP program.Anastassia Amaro, Danny Sugimoto, Sean Wharton
|Jan 24, 2023
Cardiometabolic risk factors efficacy of semaglutide in the STEP program.Anastassia Amaro, Neil S Skolnik, Danny Sugimoto
|Aug 07, 2019
IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy.Eden Miller, Ankur Doshi, Randi Grøn
|Jun 21, 2018
Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements.Danny H Sugimoto, Terry Dex, William Stager
Pageof 1
